Allergan Company Profile

What is the competitive landscape for ALLERGAN

ALLERGAN has seventy approved drugs.

There are two US patents protecting ALLERGAN drugs.

Summary for Allergan

US Patents:	2
Tradenames:	67
Ingredients:	51
NDAs:	70
Patent Litigation for Allergan:	See patent lawsuits for Allergan
PTAB Cases with Allergan as patent owner:	See PTAB cases with Allergan as patent owner

Drugs and US Patents for Allergan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	CHLOROPTIC	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	050091-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Allergan	ETHAMIDE	ethoxzolamide	TABLET;ORAL	016144-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Allergan	FIORINAL	aspirin; butalbital; caffeine	TABLET;ORAL	017534-003	Apr 16, 1986		DISCN	Yes	No
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007		DISCN	Yes	No
Allergan	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000	AB	RX	Yes	Yes
Allergan	THYROLAR-2	liotrix (t4;t3)	TABLET;ORAL	016807-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for Allergan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	ACULAR PRESERVATIVE FREE	ketorolac tromethamine	SOLUTION/DROPS;OPHTHALMIC	020811-001	Nov 3, 1997	4,454,151*PED
Allergan	DILACOR XR	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020092-002	May 29, 1992	4,839,177
Allergan	DILACOR XR	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020092-002	May 29, 1992	5,422,123
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-006	Oct 27, 2006	5,378,474
Allergan	NAMENDA	memantine hydrochloride	SOLUTION;ORAL	021627-001	Apr 18, 2005	5,061,703*PED
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997	6,258,830

Paragraph IV (Patent) Challenges for ALLERGAN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Transdermal System Extended-re	3.9 mg/24 hrs		2008-08-19
	Ophthalmic Solution	0.30%		2007-07-19
	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg		2011-12-19
	Sublingual Tablets	2.5 mg		2017-07-27
	Extended-release Capsules	60 mg		2009-03-02
	Ophthalmic Solution	0.05%		2008-10-14
	Tablets	5 mg and 10 mg		2007-10-16
	Sublingual Tablets	5 mg and 10 mg		2013-08-13

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Allecra Theraps
• Allegiance Hlthcare
• Allergan
• Allergan Herbert

Pharmaceutical Competitive Landscape Analysis: Allergan – Market Position, Strengths & Strategic Insights

Allergan, a global pharmaceutical powerhouse, has been a significant player in the healthcare industry for decades. This article delves into Allergan's market position, strengths, and strategic insights, providing a comprehensive analysis of its competitive landscape.

The Evolution of Allergan

Allergan's journey began in 1950 when pharmacist Gavin S. Herbert founded Allergan Pharmaceuticals, Inc[1]. From its humble beginnings focusing on eye care products, the company has grown into a diversified pharmaceutical giant operating in over 100 countries[2].

Key Milestones in Allergan's History

1. 1950: Establishment of Allergan Pharmaceuticals, Inc.
2. 1970: Allergan goes public
3. 1989: FDA approval of Botox for medical purposes
4. 2002: Spin-off of ophthalmic surgical and contact lens businesses
5. 2015: Acquisition by Actavis plc, later renamed Allergan plc
6. 2019: Acquisition by AbbVie Inc.

Allergan's Market Position

Allergan has established itself as a leader in several therapeutic areas, including:

1. Medical Aesthetics
2. Eye Care
3. Central Nervous System
4. Gastroenterology

In 2019, Allergan's medical aesthetics division alone generated $2,772 million in sales in the United States[10].

This impressive figure underscores Allergan's dominant position in the medical aesthetics market, particularly with its flagship product, Botox.

Global Presence and Market Reach

Allergan's operations span across 100 markets, with a strong footprint in North America, Europe, Asia Pacific, and Latin America[2]. This extensive global presence allows the company to leverage diverse market opportunities and mitigate regional risks.

Allergan's Competitive Strengths

1. Robust Product Portfolio

Allergan boasts a diverse range of products across multiple therapeutic areas. Some of its key products include:

• Botox (Medical Aesthetics and Therapeutic)
• Restasis (Eye Care)
• Linzess (Gastroenterology)
• Vraylar (Central Nervous System)

This diversified portfolio helps Allergan maintain a strong market position and reduces its dependence on any single product line.

2. Strong R&D Capabilities

Allergan's commitment to innovation is evident in its robust research and development efforts. The company invests significantly in R&D to develop new treatments and improve existing ones[4].

3. Brand Equity

Allergan has built strong brand equity, particularly in the medical aesthetics sector. Botox, for instance, has become synonymous with wrinkle treatment, giving Allergan a significant competitive advantage[2].

4. Global Distribution Network

With operations in over 100 countries, Allergan has established a robust global distribution network. This extensive reach allows the company to efficiently market and distribute its products worldwide[2].

Strategic Insights

1. Focus on High-Growth Markets

Allergan has strategically positioned itself in high-growth therapeutic areas such as medical aesthetics and eye care. This focus on lucrative markets has been a key driver of the company's growth.

2. Emphasis on Innovation

Innovation is at the heart of Allergan's strategy. The company continually invests in research and development to bring new products to market and improve existing ones[7].

3. Strategic Acquisitions and Partnerships

Allergan has a history of strategic acquisitions and partnerships to expand its product portfolio and market reach. The most notable recent example is its acquisition by AbbVie in 2019, which created a pharmaceutical powerhouse with enhanced capabilities[9].

4. Customer-Centric Approach

Allergan places a strong emphasis on understanding and meeting customer needs. This customer-centric approach has helped the company build strong relationships with healthcare providers and patients alike.

Competitive Landscape

Allergan faces competition from several major pharmaceutical companies, including:

1. Johnson & Johnson
2. Pfizer Inc.
3. AbbVie Inc.
4. Novartis AG
5. Merck & Co., Inc.[2]

Each of these competitors has its own strengths and market focus, creating a dynamic and challenging competitive landscape.

SWOT Analysis

Strengths

1. Strong brand recognition, especially for Botox
2. Diverse product portfolio
3. Global presence
4. Robust R&D capabilities

Weaknesses

1. High dependency on suppliers
2. Reliance on a small number of large wholesalers and distributors
3. Vulnerability to regulatory changes[4]

Opportunities

1. Expansion into emerging markets
2. Development of new products
3. Strategic partnerships and acquisitions

Threats

1. Intense competition from large pharmaceutical companies
2. Potential for litigation
3. Patent expirations[4]

Future Outlook

Despite facing challenges such as patent expirations and intense competition, Allergan's future looks promising. The company's strong market position, diverse product portfolio, and commitment to innovation position it well for continued growth.

The acquisition by AbbVie in 2019 has further strengthened Allergan's position, creating a combined entity with enhanced capabilities across multiple therapeutic areas[9].

Key Takeaways

1. Allergan has established itself as a leader in medical aesthetics, eye care, and other key therapeutic areas.
2. The company's diverse product portfolio and global presence are key strengths.
3. Allergan's focus on innovation and strategic acquisitions has driven its growth.
4. The company faces challenges from intense competition and regulatory pressures.
5. The acquisition by AbbVie has created new opportunities for growth and innovation.

FAQs

1. What is Allergan's most famous product? Allergan's most famous product is Botox, which is widely used for both cosmetic and therapeutic purposes.

2. How has Allergan's acquisition by AbbVie impacted the company? The acquisition has created a larger, more diversified pharmaceutical company with enhanced capabilities across multiple therapeutic areas.

3. What are Allergan's main therapeutic focus areas? Allergan's main focus areas include medical aesthetics, eye care, central nervous system disorders, and gastroenterology.

4. How does Allergan maintain its competitive edge? Allergan maintains its competitive edge through continuous innovation, strategic acquisitions, and a strong focus on high-growth markets.

5. What are the main challenges facing Allergan in the pharmaceutical industry? The main challenges include intense competition, regulatory pressures, and the need for continuous innovation to replace products facing patent expiration.

Sources cited: [1] https://en.wikipedia.org/wiki/Allergan,_Inc. [2] https://pitchgrade.com/companies/allergan-plc [4] https://www.swotandpestle.com/allergan/ [7] https://www.allerganaesthetics.com/about/our-science [9] https://www.abbvie.com/allergan.html [10] https://www.statista.com/statistics/973714/allergan-us-specialized-product-sales-by-therapeutic-area/